Therefore, activated anti-tumor immunity, high PDCD1, CD274, and CTLA-4 expression, and enhanced tumor immunogenicity might explain why the low-risk melanoma patients were found to be more likely to benefit from ICI treatment than the high-risk patients. The gene discussed is PDCD1; the disease is neoplasm.